Layer3.news

AI by layer3.news

Filtering by: Myles Minter · clear filter

HOW ARGENX'S 'BLOWOUT' QUARTER SPARKED A BLAZING 31% MONTHLONG RUN

https://www.investors.com/wp-content/uploads/2025/08/NEWAM_antibody_081525_adobe.jpg

✍️ Argenx's stock surged after its 'blowout' second-quarter report, driven by the success of its Vyvgart treatment for autoimmune diseases.

👉 Vyvgart treatment approved for several autoimmune diseases 👉 New formulations and treatments in development 👉 Analysts optimistic about company's future 👉 Strong pipeline and growth potential

-- #ThomasSmith #MylesMinter #DavidNierengarten #AllisonGatlin #health

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqdyrvyytl38yuwh4nhxap0lpe5ymuknm3czr6acm5vfw75jgglhwqptyk77

Thomas Smith Myles Minter David Nierengarten Allison Gatlin health mainstream:perspective

8/17/2025

npub1vap2usg…grwc3n

WHY VERTEX PHARMA IS FEELING THE PAIN DESPITE A SECOND-QUARTER BEAT

https://www.investors.com/wp-content/uploads/2019/03/stock-Vertex-03-shutter.jpg

✍️ Vertex Pharmaceuticals' stock plummeted after the company announced it would not advance its next-generation pain drug, VX-993, into additional testing due to a lackluster midstage study.

👉 Vertex will not advance its next-generation pain drug, VX-993, into additional testing due to a lackluster midstage study 👉 The company will not pursue additional testing for its approved pain drug, Journavx, as a treatment for broad neuropathic pain 👉 Vertex will focus on diabetic neuropathy, a smaller market, instead 👉 Strong second-quarter report with $2.96 billion in sales and adjusted profit of $4.52 per share

-- #BrianAbrahams #DavidAltshuler #MarkBunnage #MylesMinter #JosephStringer #DavidRisinger #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqw7cqy2qsp5zexwdwc8rwhq7xx8lkz2thw33jdrrpdxm2cyj6usvq8k7kg8

Brian Abrahams David Altshuler Mark Bunnage Myles Minter Joseph Stringer David Risinger business mainstream:perspective

8/5/2025

npub1vap2usg…grwc3n

REGENERON CANCER BISPECIFIC REJECTED AGAIN; ALLOGENE DISCLOSES TRIAL DEATH

https://s.yimg.com/ny/api/res/1.2/U4j2o5pPobTPdKaxkHAVsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259

✍️ Regeneron Pharmaceuticals and Allogene Therapeutics faced setbacks in their drug development, while Bristol Myers Squibb and Biogen reported positive earnings and sales results.

👉 Regeneron Pharmaceuticals' two new drugs hit regulatory setbacks due to FDA inspection issues 👉 Allogene Therapeutics stopped using an experimental immunosuppressive antibody after a study participant died 👉 Bristol Myers Squibb boosted its revenue outlook for 2025 driven by higher-than-expected sales of Revlimid 👉 Biogen's latest earnings report surpassed Wall Street expectations 👉 Argenx's quarterly sales numbers for Vyvgart topped investor expectations

-- #JonathanGardner #BenFidler #BrianAbrahams #JacobBell #MylesMinter #ThomasSmith #JulieGilmore #health

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqrmevwawehs2r0zuvhmh60790hxcsaeexrphruex9n69w9y02avrqjkjjk9

Jonathan Gardner Ben Fidler Brian Abrahams Jacob Bell Myles Minter Thomas Smith Julie Gilmore health

8/2/2025

npub1vap2usg…grwc3n

SANOFI INKS A $470 MILLION ALZHEIMER'S DEAL, SENDING THIS DOLLAR STOCK FLYING

https://www.investors.com/wp-content/uploads/2022/06/Stock-sanofi-04-adobe.jpg

✍️ Vigil Neuroscience's stock tripled after Sanofi agreed to buy it for $470 million plus a contingent value right tied to its experimental Alzheimer's treatment.

👉 Sanofi agreed to buy Vigil Neuroscience for $470 million plus a contingent value right 👉 Deal is expected to close in the third quarter 👉 Contingent value right worth $2 a share tied to first commercial sale of VG-3927 👉 VG-3927 targets TREM2, a neuroinflammation target 👉 Deal is considered full and fair given the stage of development of VG-3927

-- #LaurenChico #MylesMinter #AllisonGatlin #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqnyz66auy0vppwhae74zj6nnpagxfvdkzeyd6xrvm284d6dc4xrss6ajyn5

Lauren Chico Myles Minter Allison Gatlin business mainstream:perspective

5/22/2025

npub1vap2usg…grwc3n

WHY DID VERTEX PHARMACEUTICALS STOCK FALL ON TUESDAY?

https://media.zenfs.com/en/Benzinga/97d095c5541b6caa59736c8aa2956ce7

✍️ Vertex Pharmaceuticals reported lower-than-expected first-quarter 2025 earnings, missing consensus estimates.

👉 Vertex reported lower-than-expected first-quarter 2025 earnings 👉 Revenue increased by 3%, driven by Trikafta/Kaftrio and Alyftrek 👉 Company raised the low end of its total revenue guidance by $100 million 👉 Vertex paused the multiple ascending dose portion of the Phase 1/2 study of VX-522 due to a tolerability issue

-- #ReshmaKewalramani #MylesMinter #WilliamBlair #U.S. #Russia #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqysfnqc28tr0pxdtkk0gmrz6cx3ftm0djj46d33amuf4vg2z7jzjsgc0hmz

Reshma Kewalramani Myles Minter William Blair U.S.Russia business mainstream:perspective

5/8/2025

npub1vap2usg…grwc3n

VERTEX PHARMACEUTICALS TOPPLES 12% ON A SERIES OF FIRST-QUARTER SETBACKS

https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg

✍️ Vertex Pharmaceuticals' stock plummeted 12% after the company reported disappointing first-quarter earnings, citing slow uptake for new drugs and a paused messenger RNA study.

👉 Vertex Pharmaceuticals' stock plummeted 12% after reporting disappointing first-quarter earnings 👉 Sales missed expectations, and adjusted earnings fell 15% 👉 New non-opioid pain treatment, Journavx, had insignificant sales 👉 Cystic fibrosis drug, Alyftrek, had light revenue 👉 Company reported a $100 million headwind from Russia due to an unauthorized copy of Trikafta

-- #DavidRisinger #BrianAbrahams #MylesMinter #ManiForoohar #AllisonGatlin #Russia #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq5vjhrc964l25py2mlqpwuykcgh593d79axn2f926ngrq6j6h4vesju99vc

David Risinger Brian Abrahams Myles Minter Mani Foroohar Allison Gatlin Russia business mainstream:perspective

5/6/2025

npub1vap2usg…grwc3n

NEUROCRINE CRUMBLES ON LACKLUSTER GUIDANCE FOR ITS BREAD-AND-BUTTER DRUG

https://www.investors.com/wp-content/uploads/2024/04/Stock-neurocrinebio-02-shutt.jpg

✍️ Neurocrine Biosciences' stock plummeted 14% to a three-month low after its drug Ingrezza's sales and 2025 guidance fell short of Wall Street's expectations.

👉 Ingrezza sales came in at $615 million, missing analysts' call for $623 million 👉 2025 guidance expects $2.5 billion to $2.6 billion in sales, missing analysts' call for $2.67 billion 👉 Stock tumbled 14% to 128.76, sending shares into a sell zone

-- #MarcGoodman #BrianAbrahams #MylesMinter #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq09cynqg735h2dtgmrzeaztp058mypdnvlr98aa44julsljrxjp9s26mmsl

Marc Goodman Brian Abrahams Myles Minter business mainstream:perspective

2/7/2025

npub1hv7cr6w…das995

NEUROCRINE JUMPS AFTER SNAGGING FDA APPROVAL FOR A FIRST-IN-DECADES DRUG

https://s.yimg.com/uu/api/res/1.2/aNZJQCHoAawUo8sMO5qyAw--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/0a36ee0f18bca8e1e3e845322c51abdc

✍️ Neurocrine Biosciences (NBIX) stock surged after the company received FDA approval for its new drug, Crenessity, which treats congenital adrenal hyperplasia in adults and children.

👉 Neurocrine Biosciences received FDA approval for its new drug, Crenessity, which treats congenital adrenal hyperplasia in adults and children. 👉 Crenessity is the first new treatment for adrenal disease in decades. 👉 The drug will be an important change for patients, who have previously had to use glucocorticoids to treat their condition. 👉 Neurocrine Chief Executive Kyle Gano believes that Crenessity will change the standard of care for patients with congenital adrenal hyperplasia.